Osteoporosis risk assessment and ethnicity: validation and comparison of 2 clinical risk stratification instruments
- PMID: 16808748
- PMCID: PMC1924607
- DOI: 10.1111/j.1525-1497.2006.00459.x
Osteoporosis risk assessment and ethnicity: validation and comparison of 2 clinical risk stratification instruments
Abstract
Background: Dual energy x-ray absorptiometry (DXA), coupled with early treatment, may reduce morbidity and mortality associated with osteoporosis. Clinical tools to enhance selection of women for DXA screening have not been developed or validated in an ethnically diverse population.
Objective: To compare the performance of the osteoporosis risk assessment instrument (ORAI) and the simple calculated osteoporosis risk estimation (SCORE) instrument across 3 racial/ethnic groups to identify women who would benefit from DXA scans.
Design: Blinded comparison of the instruments in a cross-sectional sample.
Participants: Two-hundred twenty-six postmenopausal women were recruited from a university-based family medicine clinic. Women with a prior diagnosis of osteoporosis or those taking bone active medications were excluded.
Measurements: Participants completed a questionnaire that contained the ORAI and the SCORE questions; 203 completed a DXA scan.
Results: The sensitivity and specificity for the ORAI (0.68, [0.49 to 0.88, 95% CI]; 0.66, [0.59 to 0.73, 95% CI]) and the SCORE instrument (0.54, [0.34 to 0.75, 95% CI]; 0.72, [0.65 to 0.78, 95% CI]) differed significantly from previous reports. Overall, the accuracy of the ORAI (66.5%) and SCORE instrument (70.0%) were similar (McNemar's test P value = .37). The accuracy between instruments differed significantly in African-American women (McNemar's test, P value <.001). In African Americans, the SCORE instrument correctly identified more women without osteoporosis, but missed 70% of those with osteoporosis.
Conclusions: The performance of the ORAI and SCORE instrument differed significantly from previous reports. Although both can reduce the use of DXA scans for screening for osteoporosis, lower sensitivities resulted in underrecognition of osteoporosis and may limit their clinical usefulness in an ethnically diverse population.
Figures

Similar articles
-
Evaluation of decision rules for identifying low bone density in postmenopausal African-American women.J Natl Med Assoc. 2004 Mar;96(3):290-6. J Natl Med Assoc. 2004. PMID: 15040510 Free PMC article.
-
Development and validation of the Osteoporosis Risk Assessment Instrument to facilitate selection of women for bone densitometry.CMAJ. 2000 May 2;162(9):1289-94. CMAJ. 2000. PMID: 10813010 Free PMC article.
-
Evaluation of decision rules for referring women for bone densitometry by dual-energy x-ray absorptiometry.JAMA. 2001 Jul 4;286(1):57-63. doi: 10.1001/jama.286.1.57. JAMA. 2001. PMID: 11434827
-
Dual-energy X-ray Absorptiometry.J Clin Densitom. 2017 Jul-Sep;20(3):291-303. doi: 10.1016/j.jocd.2017.06.014. Epub 2017 Jul 14. J Clin Densitom. 2017. PMID: 28716497 Review.
-
Performance of Osteoporosis Self-Assessment Tool (OST) in Predicting Osteoporosis-A Review.Int J Environ Res Public Health. 2018 Jul 9;15(7):1445. doi: 10.3390/ijerph15071445. Int J Environ Res Public Health. 2018. PMID: 29987247 Free PMC article. Review.
Cited by
-
The relationship between sodium intake and some bone minerals and osteoporosis risk assessment instrument in postmenopausal women.Med J Islam Repub Iran. 2016 May 28;30:377. eCollection 2016. Med J Islam Repub Iran. 2016. PMID: 27493921 Free PMC article.
-
Development and validation of osteoporosis prescreening model for Iranian postmenopausal women.J Diabetes Metab Disord. 2015 Mar 17;14:12. doi: 10.1186/s40200-015-0140-7. eCollection 2015. J Diabetes Metab Disord. 2015. PMID: 25821747 Free PMC article.
-
Risk assessment instruments for screening bone mineral density in a Mediterranean population.World J Orthop. 2016 Sep 18;7(9):577-83. doi: 10.5312/wjo.v7.i9.577. eCollection 2016 Sep 18. World J Orthop. 2016. PMID: 27672571 Free PMC article.
-
AI-based opportunistic quantitative image analysis of lung cancer screening CTs to reduce disparities in osteoporosis screening.Bone. 2024 Sep;186:117176. doi: 10.1016/j.bone.2024.117176. Epub 2024 Jun 24. Bone. 2024. PMID: 38925254
-
Clinical performance of osteoporosis risk assessment tools in women aged 67 years and older.Osteoporos Int. 2008 Aug;19(8):1175-83. doi: 10.1007/s00198-007-0555-1. Epub 2008 Jan 25. Osteoporos Int. 2008. PMID: 18219434 Free PMC article.
References
-
- Ray N, Chan J, Thamer M, Melton M. Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation. J Bone Miner Res. 1997;12:24–35. - PubMed
-
- Black D, Cummings S, Karpf D, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet. 1996;347:1535–41. - PubMed
-
- Black D, Thompson D, Bauer D, et al. Fracture risk reduction with alendronate in women with osteoporosis: the fracture intervention trial. J Clin Endocrinol Metab. 2000;85:4118–24. - PubMed
-
- Bone H, Greenspan S, McKeever C, et al. Alendronate and estrogen effects in postmenopausal women with low bone mineral density. J Clin Endocrinol Metab. 2000;85:720–6. - PubMed
-
- Downs RJ, Bell N, Ettinger M, et al. Comparison of alendronate and intranasal calcitonin for treatment of osteoporosis in postmenopausal women. J Clin Endocrinol Metab. 2000;85:1783–8. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical